Common use of Supplementary Data Clause in Contracts

Supplementary Data. Figure S1. Age at breast cancer development (black bars) and ovarian cancer development (grey bars) for the carriers of BRCA1*R1699Q. Figure S2. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming constant relative risk. Figure S3. Cumulative risks (%) for breast cancer (left graph) and ovarian cancer (right graph) by age for carriers of BRCA1*R1699Q based on the main analysis (blue line), sub-analysis 1 (orange line) and sub-analysis 2 (purple line). The corresponding curves or the cumulative risk conferred by average pathogenic BRCA1 variants (red line) and for the general population (green line) are also shown. Cumulative risks are calculated using segregation analysis, major gene model assuming relative risk as a continuous, piecewise linear function of age. Table S1. Number and origin of families in the previous study and current study (previous plus newly included families) . Previous study10 Current study Country # Families # Families with additional genotyping (*) # Families # Families with additional genotyping (*) The Netherlands 12 3 20 15 Denmark 10 4 22 19 France 5 3 14 7 Germany 5 1 19 10 South Africa 1 1 1 1 Sweden 14 5 20 17 United Kingdom 4 2 4 2 U.S.A. 9 7 14 11 Total 69 30 129 91 (*): additional genotyping means at least one other relative tested in addition to the index. Table S2. Descriptive characteristics of the 129 families. Unknown Carriership Non-carriers Carriers Age Total BC# OC& Total BC OC Total BC OC <30 2935 1 0 100 0 0 105 4 0 30-39 89 18 2 8 1 0 37 26 1 40-49 94 26 5 27 5 0 60 39 8 50-59 124 40 26 24 4 1 53 30 24 60-69 122 36 15 6 2 0 39 11 12 70-79 96 16 7 4 2 1 11 3 6 >=80 82 10 2 4 1 0 4 0 1 Total 3542 147 57 173 15 2 309 113 52 #BC: Breast cancer &OC: Ovarian cancer 3 Table S3. Cumulative risk (95% Confidence Interval) using segregation analysis, major gene models assuming constant relative risk. Main Analysis Cumulative risk (95% Confidence Interval) Sub-Analysis 1 Cumulative risk (95% Confidence Interval) Sub-Analysis 2 Cumulative risk (95% Confidence Interval) Age Breast cancer Ovarian cancer Breast cancer Ovarian cancer Breast cancer Ovarian cancer 25 0.017 0.15 0.02 0.14 0.02 0.10 (0.010, 0.024) (0.06, 0.24) (0.01, 0.03) (0.04, 0.24) (0.01, 0.03) (0.03, 0.17) 30 0.13 0.26 0.16 0.26 0.14 0.17 (0.07, 0.18) (0.12, 0.41) (0.07, 0.24) (0.10, 0.41) (0.05, 0.23) (0.06, 0.28) 35 0.49 0.42 0.60 0.40 0.54 0.27 (0.31, 0.68) (0.21, 0.62) (0.32, 0.88) (0.17, 0.63) (0.23, 0.85) (0.11, 0.43) 40 1.34 0.63 1.63 0.61 1.47 0.41 (0.90, 1.78) (0.34, 0.92) (0.95, 2.31) (0.29, 0.93) (0.72, 2.21) (0.18, 0.63) 45 2.97 0.95 3.60 0.92 3.24 0.62 (2.08, 3.85) (0.52, 1.38) (2.23, 4.96) (0.45, 1.38) (1.74, 4.72) (0.29, 0.95) 50 5.40 1.49 6.54 1.44 5.89 0.97 (3.96, 6.82) (0.81, 2.17) (4.31, 8.71) (0.69, 2.18) (3.45, 8.28) (0.45, 1.49) 55 8.82 2.28 10.63 2.20 9.61 1.49 (6.68, 10.90) (1.25, 3.29) (7.36, 13.79) (1.08, 3.31) (5.99, 13.09) (0.70, 2.27) 60 12.38 3.36 14.87 3.25 13.47 2.20 (9.72, 14.97) (1.89, 4.81) (10.81, 18.74) (1.64, 4.83) (8.96, 17.75) (1.07, 3.32) 65 16.42 4.81 19.62 4.65 17.82 3.15 (13.23, 19.49) (2.78, 6.79) (14.80, 24.16) (2.42, 6.82) (12.43, 22.87) (1.58, 4.70) 70 20.58 6.42 24.47 6.21 22.28 4.22 (16.95, 24.05) (3.87, 8.90) (19.04, 29.53) (3.41, 8.92) (16.17, 27.95) (2.24, 6.17)